These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 24566736)

  • 1. Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.
    Yu H; Steeghs N; Nijenhuis CM; Schellens JH; Beijnen JH; Huitema AD
    Clin Pharmacokinet; 2014 Apr; 53(4):305-25. PubMed ID: 24566736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Drug Monitoring for Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma.
    Henriksen JN; Andersen CU; Fristrup N
    Clin Genitourin Cancer; 2024 Jun; 22(3):102064. PubMed ID: 38555681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care.
    Lankheet NA; Knapen LM; Schellens JH; Beijnen JH; Steeghs N; Huitema AD
    Ther Drug Monit; 2014 Jun; 36(3):326-34. PubMed ID: 24305627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib.
    Lankheet NAG; Desar IME; Mulder SF; Burger DM; Kweekel DM; van Herpen CML; van der Graaf WTA; van Erp NP
    Br J Clin Pharmacol; 2017 Oct; 83(10):2195-2204. PubMed ID: 28500677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized dose.
    Westerdijk K; Desar IME; Steeghs N; van der Graaf WTA; van Erp NP;
    Br J Clin Pharmacol; 2020 Feb; 86(2):258-273. PubMed ID: 31782166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.
    Widmer N; Bardin C; Chatelut E; Paci A; Beijnen J; Levêque D; Veal G; Astier A
    Eur J Cancer; 2014 Aug; 50(12):2020-36. PubMed ID: 24928190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
    Haouala A; Zanolari B; Rochat B; Montemurro M; Zaman K; Duchosal MA; Ris HB; Leyvraz S; Widmer N; Decosterd LA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):1982-96. PubMed ID: 19505856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations.
    Teo YL; Ho HK; Chan A
    Br J Clin Pharmacol; 2015 Feb; 79(2):241-53. PubMed ID: 25125025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacokinetic issues on cancer pharmacotherapy].
    Tanigawara Y
    Nihon Rinsho; 2015 Aug; 73(8):1357-63. PubMed ID: 26281690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors.
    Terada T; Noda S; Inui K
    Pharmacol Ther; 2015 Aug; 152():125-34. PubMed ID: 25976912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How 'Optimal' are Optimal Sampling Times for Tyrosine Kinase Inhibitors in Cancer? Practical Considerations.
    Ward MB; Reuter SE; Martin JH
    Clin Pharmacokinet; 2016 Oct; 55(10):1171-1177. PubMed ID: 27085335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individualized dosing of tyrosine kinase inhibitors: are we there yet?
    de Wit D; Guchelaar HJ; den Hartigh J; Gelderblom H; van Erp NP
    Drug Discov Today; 2015 Jan; 20(1):18-36. PubMed ID: 25245169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapeutic drug monitoring of tyrosine-kinase inhibitors in the treatment of chronic myelogenous leukaemia: interests and limits].
    Bouchet S; Royer B; Le Guellec C; Titier K;
    Therapie; 2010; 65(3):213-8. PubMed ID: 20699073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.
    Di Gion P; Kanefendt F; Lindauer A; Scheffler M; Doroshyenko O; Fuhr U; Wolf J; Jaehde U
    Clin Pharmacokinet; 2011 Sep; 50(9):551-603. PubMed ID: 21827214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels.
    Gotta V; Widmer N; Montemurro M; Leyvraz S; Haouala A; Decosterd LA; Csajka C; Buclin T
    Clin Pharmacokinet; 2012 Mar; 51(3):187-201. PubMed ID: 22339450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic Targets for Therapeutic Drug Monitoring of Small Molecule Kinase Inhibitors in Pediatric Oncology.
    Janssen JM; Dorlo TPC; Steeghs N; Beijnen JH; Hanff LM; van Eijkelenburg NKA; van der Lugt J; Zwaan CM; Huitema ADR
    Clin Pharmacol Ther; 2020 Sep; 108(3):494-505. PubMed ID: 32022898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.
    Deng J; Shao J; Markowitz JS; An G
    Pharm Res; 2014 Sep; 31(9):2237-55. PubMed ID: 24842659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insight to Pharmacokinetics of TKIs: Optimizing Practical Guidelines for Individualized Therapy.
    Wang R; Zhong C; Zhang C; Hua M; Ma D
    Curr Drug Metab; 2017; 18(3):199-206. PubMed ID: 28093990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Drug Monitoring of Targeted Anticancer Protein Kinase Inhibitors in Routine Clinical Use: A Critical Review.
    Cardoso E; Guidi M; Blanchet B; Schneider MP; Decosterd LA; Buclin T; Csajka C; Widmer N
    Ther Drug Monit; 2020 Feb; 42(1):33-44. PubMed ID: 31479043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children.
    Centanni M; Zaher O; Elhad D; Karlsson MO; Friberg LE
    Cancer Chemother Pharmacol; 2024 Aug; 94(2):297-310. PubMed ID: 38782791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.